<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>9805051</identifier>
<setSpec>0375-0760</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Chiang Macía, A</dc:author>
<dc:author>Pedroso Flaquet, P</dc:author>
<dc:author>Rodríguez Lay, L</dc:author>
<dc:author>Díaz Acosta, D</dc:author>
<dc:author>López-Chávez, A U</dc:author>
<dc:author>Díaz González, M</dc:author>
<dc:author>Bravo González, J R</dc:author>
<dc:description xml:lang="en">The Cuban recombinant vaccine against hepatitis B virus was applied with doses of 10 ìg to children under 15 in a scheme from 0, 1 to 6 months. The immunogenicity was evaluated at 2, 7, and 12 months and showed 100% of seroconversion with protective titres. 65.9, 100, and 83.5% of the vaccinated attained titres higher that 100 UI/L at 60, 210, and 360 days. The geometrical mean was of 213.6, 8208.2, and 568.0 UI/L, respectively. All the groups obtained 100% of seroconversion; however, there were significant differences (p &lt; 0.05) in favor of the preschool and school children compared with those over 10 as regards the response level (titres higher than 100 UI/L) and the geometrical mean of antibody titres in the 3 samples. It was demonstrated the high immunogenic power of the vaccine at these ages, which makes it recommendable for their protection against the hepatitis B virus (HBV).</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>1996 </dc:date>
<dc:title xml:lang="es">Inmunogenicidad de la vacuna Heberbiovac-HB en niños.</dc:title>
<dc:title xml:lang="en">[The immunogenicity of the Heberbiovac-HB vaccine in children].</dc:title>
<dc:publisher>Revista cubana de medicina tropical</dc:publisher>
</metadata>
</record>
</pubmed-document>
